BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30999314)

  • 1. Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer.
    Larsen FO; Jensen BV; Nørgaard HH; Hermann HK; Larsen PN; Markussen A; Hogdall E; Nielsen D
    Oncology; 2019; 96(6):299-308. PubMed ID: 30999314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
    Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
    Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases.
    Pernot S; Velut G; Kourie RH; Amouyal G; Sapoval M; Pointet AL; Landi B; Zaimi Y; Lepère C; Pellerin O; Taieb J
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):255-260. PubMed ID: 29233520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.
    Wei L; Chen J; Wen J; Wu D; Ma X; Chen Z; Huang J
    Med Sci Monit; 2020 Feb; 26():e919031. PubMed ID: 32062671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure.
    Sato Y; Inaba Y; Ura T; Nishiofuku H; Yamaura H; Kato M; Takahari D; Tanaka T; Muro K
    J Gastrointest Cancer; 2018 Jun; 49(2):132-137. PubMed ID: 28058527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
    Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
    Bouchahda M; Boige V; Smith D; Karaboué A; Ducreux M; Hebbar M; Lepère C; Focan C; Guimbaud R; Innominato P; Awad S; Carvalho C; Tumolo S; Truant S; De Baere T; Castaing D; Rougier P; Morère JF; Taieb J; Adam R; Lévi F;
    Eur J Cancer; 2016 Nov; 68():163-172. PubMed ID: 27768923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
    Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
    Pfeiffer P; Sorbye H; Qvortrup C; Karlberg M; Kersten C; Vistisen K; Lindh B; Bjerregaard JK; Glimelius B
    Clin Colorectal Cancer; 2015 Sep; 14(3):170-6. PubMed ID: 25956187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
    Ducreux M; Ychou M; Laplanche A; Gamelin E; Lasser P; Husseini F; Quenet F; Viret F; Jacob JH; Boige V; Elias D; Delperro JR; Luboinski M;
    J Clin Oncol; 2005 Aug; 23(22):4881-7. PubMed ID: 16009952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
    Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
    BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
    Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
    J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
    Boilève A; De Cuyper A; Larive A; Mahjoubi L; Najdawi M; Tazdait M; Gelli M; Tselikas L; Smolenschi C; Malka D; Pignon JP; Ducreux M; Boige V
    Eur J Cancer; 2020 Oct; 138():89-98. PubMed ID: 32871526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.
    Ghiringhelli F; Vincent J; Bengrine L; Borg C; Jouve JL; Loffroy R; Guiu B; Blanc J; Bertaut A
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2357-2363. PubMed ID: 31273511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study.
    Lim A; Le Sourd S; Senellart H; Luet D; Douane F; Perret C; Bouvier A; Métairie S; Cauchin E; Rougier P; Matysiak-Budnik T; Touchefeu Y
    Clin Colorectal Cancer; 2017 Dec; 16(4):308-315. PubMed ID: 28433600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.
    Link KH; Pillasch J; Formentini A; Sunelaitis E; Leder G; Safi F; Kornmann M; Beger HG
    Eur J Surg Oncol; 1999 Aug; 25(4):381-8. PubMed ID: 10419708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
    Ku GY; Haaland BA; de Lima Lopes G
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil for Patients with Unresectable Liver Metastases from Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter Retrospective Study.
    Sato Y; Inaba Y; Aramaki T; Sone M; Morita Y; Nishiofuku H; Tanaka T; Miyazaki M; Matsueda K; Arai Y
    Oncology; 2020; 98(5):267-272. PubMed ID: 32092755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
    BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.